Threshold Pharmaceuticals (THLD) jumps 13.5% after the FDA reaches an agreement for the Phase...

|About: Threshold Pharmaceuticals... (THLD)|By:, SA News Editor

Threshold Pharmaceuticals (THLD) jumps 13.5% after the FDA reaches an agreement for the Phase III trial of TH-302 for the treatment of pancreatic cancer. The study will be conducted by Germany's Merck, Threshold's partner in the development of TH-302. (PR)